Large scale and clinical grade purification of syndecan-1+ malignant plasma cells (scientific article published on June 23, 1997)

Q43604319	Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase 1 study
Q38518964	An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.
Q40169401	B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro
Q38312824	Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma
Q32062991	Identification and location on syndecan‐1 core protein of the epitopes of B‐B2 and B‐B4 monoclonal antibodies
Q73209300	Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage
Q36453354	Microarray-based understanding of normal and malignant plasma cells
Q47901564	Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications.
Q42543880	The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells

P356	DOI	10.1016/S0022-1759(97)00056-2
P953	full work available at URL	https://api.elsevier.com/content/article/PII:S0022175997000562?httpAccept=text/plain
		https://api.elsevier.com/content/article/PII:S0022175997000562?httpAccept=text/xml
P698	PubMed publication ID	9236917